The drug, Xacduro (sulbactam for injection; durlobactam for injection), works to simultaneously protect itself and kill A. baumannii. In a phase 3 trial, 19 percent of Xacduro patients died, compared to 32 percent of deaths among those who took colistin, a comparator antibiotic.
A. baumannii tops the World Health Organization’s list of critical pathogens that pose a high risk to human health, and the bacteria “can become highly resistant to multiple antibacterial drugs and current treatment options for drug-resistant A. baumannii are limited,” the FDA said.
Xacduro, made by Entasis Therapeutics, is approved for adults.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.